Duchenne Breakthrough Hopes Rise With More Data From Sarepta Gene Therapy
Phase II Data Bodes Well For Pivotal EMBARK Trial
Executive Summary
More data from Sarepta’s mid-stage studies help bolster confidence in the gene therapy but will the US FDA call in the drug for an early appraisal or await Phase III data next year?
You may also be interested in...
Sarepta’s Exondys Successor Bounces Back From Clinical Hold But All Eyes On Gene Therapy
The firm’s exon-skipping Duchenne muscular dystrophy asset will resume clinical study in the US following the lifting of a clinical hold but observers seem more invested in the fate of its gene therapy candidate for the condition.
Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death
The death in Pfizer’s Phase I study could reflect wider safety issues for AAV-based gene therapy and could spur intervention from regulators in 2022.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.